Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Gallo G, Strober B, Van Voorhees A. Lockshin B, et al. Among authors: van voorhees a. Dermatol Ther. 2021 Mar;34(2):e14808. doi: 10.1111/dth.14808. Epub 2021 Feb 15. Dermatol Ther. 2021. PMID: 33491259 Free PMC article.
National Psoriasis Foundation clinical consensus on disease severity.
Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ; National Psoriasis Foundation. Pariser DM, et al. Arch Dermatol. 2007 Feb;143(2):239-42. doi: 10.1001/archderm.143.2.239. Arch Dermatol. 2007. PMID: 17310004
OBJECTIVES: A task force of the National Psoriasis Foundation Medical Board was convened to evaluate the current severity criteria of mild, moderate, and severe psoriasis and to make recommendations concerning a 2-tiered categorization of severity based on current c …
OBJECTIVES: A task force of the National Psoriasis Foundation Medical Board was convened to evaluate the current severity criteria of …
Consensus guidelines for the management of plaque psoriasis.
Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Hsu S, et al. Among authors: van voorhees as. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410. Arch Dermatol. 2012. PMID: 22250239
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry.
Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, Mason M, Guo N, McLean RR, Greenberg JD, Van Voorhees AS. Merola JF, et al. Among authors: van voorhees as. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2051-2058. doi: 10.1111/jdv.16274. Epub 2020 Jun 9. J Eur Acad Dermatol Venereol. 2020. PMID: 32027420
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y. Van Voorhees AS, et al. J Am Acad Dermatol. 2020 Jul;83(1):96-103. doi: 10.1016/j.jaad.2020.01.072. Epub 2020 Feb 4. J Am Acad Dermatol. 2020. PMID: 32032692 Free article. Clinical Trial.
136 results